Drugs targeting Bcl-2 family members as an emerging strategy in cancer

Expert Reviews in Molecular Medicine

Volumn 12, Issue , 2010, Pages

  Leber, Brian ^a   Geng, Fei ^a   Kale, Justin ^a   Andrews, David W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; CASPASE; GX 15 70; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; PYRROLE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER GROWTH; CELLULAR STRESS RESPONSE; CHRONIC LYMPHATIC LEUKEMIA; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HUMAN; LYMPHOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASM;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SULFONAMIDES;

EID: 79952112980     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399410001572     Document Type: Review

References (96)

1. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70 (Pubitemid 30046295)
2. Ellis, H.M. and Horvitz, H.R. (1986) Genetic control of programmed cell death in the nematode C. elegans. Cell 44, 817-829 (Pubitemid 16045328)
3. Bakhshi, A. et al. (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41, 899-906 (Pubitemid 15243395)
4. Cleary, M.L., Smith, S.D. and Sklar, J. (1986) Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47, 19-28 (Pubitemid 17181529)
5. Tsujimoto, Y. et al. (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097-1099 (Pubitemid 15217831)
6. McDonnell, T.J. et al. (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79-88 (Pubitemid 19098870)
7. Hengartner, M.O. and Horvitz, H.R. (1994) C. elegans cell survival gene ced-9 encodes a functional homolog of the mammanproto-oncogene bcl-2. Cell 76, 665-676 (Pubitemid 24070651)
8. Green, D.R. and Evan, G.I. (2002)Amatter of life and death. Cancer Cell 1, 19-30
9. Look, A.T. (1997) Oncogenic transcription factors in the human acute leukemias. Science 278, 1059-1064
10. Slavov, N. and Dawson, K.A. (2009) Correlation signature of the macroscopic states of the gene regulatory network in cancer. Proceedings of the National Academyof Sciences of the United States of America 106, 4079-4084
11. Beroukhim, R. et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905
12. Brown, J.M. and Attardi, L.D. (2005) The role of apoptosis in cancer development and treatment response. Nature Reviews Cancer 5, 231-237 (Pubitemid 40314954)
13. Kang, M.H. and Reynolds, C.P. (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research 15, 1126-1132
14. Schmidt, C. (2009) Why do tumors become resistant to antiangiogenesis drugs? Journal of the National Cancer Institute 101, 1530-1532
15. Youle, R.J. and Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 9, 47-59
16. Giam, M., Huang, D.C. and Bouillet, P. (2008) BH3-only proteins and their roles in programmed cell death. Oncogene 1 (Suppl), 128-136
17. Gavathiotis, E. et al. (2008) BAX activation is initiated at a novel interaction site. Nature 455, 1076-1081
18. Kim, H. et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nature Cell Biology 8, 1348-1358 (Pubitemid 44835109)
19. Letai, A. et al. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192 (Pubitemid 41043974)
20. Chen, L. et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 17, 393-403 (Pubitemid 40193310)
21. Willis, S.N. et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859
22. Billen, L.P. et al. (2008) Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biology 6, e147
23. Leber, B., Lin, J. and Andrews, D.W. (2007) Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 12, 897-911 (Pubitemid 46653294)
24. Lovell, J.F. et al. (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074-1084
25. Felsher, D.W. (2008) Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Research 68, 3081-3086
26. Tolomeo, M. et al. (2009) Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Anticancer Agents in Medicinal Chemistry 9, 853-863
27. Letai, A. et al. (2004) Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6, 241-249 (Pubitemid 39222037)
28. Del Gaizo Moore, V. et al. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. Journal of Clinical Investigation 117, 112-121
29. Letai, A.G. (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Reviews Cancer 8, 121-132
30. Certo, M. et al. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-365 (Pubitemid 43668734)
31. Brunelle, J.K. and Letai, A. (2009) Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science 122, 437-441
32. Deng, J. et al. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171-185 (Pubitemid 47199122)
33. Pro, B. et al. (2008) Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology 143, 355-360
34. O'Brien, S. et al. (2009) 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. Journal of Clinical Oncology 27, 5208-5212
35. Adis International Limited (2007) Oblimersen: augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. Drugs in R&D 8, 321-334
36. Vogler, M. et al. (2009) Different forms of cell death induced by putative BCL2 inhibitors. Cell Death and Differentiation 16, 1030-1039
37. Nguyen, M. et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America 104, 19512-19517
38. Oltersdorf, T. et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (Pubitemid 40825512)
39. Kang, M.H. et al. (2007) Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110, 2057-2066 (Pubitemid 47443923)
40. Konopleva, M. et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375-388 (Pubitemid 44693472)
41. Van Delft, M.F. et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399
42. Chen, S. et al. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Research 67, 782-791 (Pubitemid 46192219)
43. Hauck, P. et al. (2009) Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Molecular Cancer Therapeutics 8, 883-892
44. Lin, X. et al. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26, 3972-3979 (Pubitemid 46884293)
45. Tse, C. et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research 68, 3421-3428
46. Shore, G.C. and Viallet, J. (2005) Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology American Society of Hematology. Education Program 2005, 226-230
47. Zhai, D. et al. (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death and Differentiation 13, 1419-1421 (Pubitemid 44057478)
48. Lee, E.F. et al. (2009a) Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands. Journal of Biological Chemistry 284, 30508-30517
49. Lee, E.F. et al. (2009b) Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins. Journal of Biological Chemistry 284, 31315-31326
50. Zhong, Q. et al. (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095 (Pubitemid 40884398)
51. Yu, C. et al. (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869 (Pubitemid 41509409)
52. Schwickart, M. et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463, 103-107
53. Dlugosz, P.J. et al. (2006) Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO Journal 25, 2287-2296 (Pubitemid 44012212)
54. Kim, P.K. et al. (2004) During apoptosis bcl-2 changes membrane topologyat both the endoplasmic reticulum and mitochondria. Molecular Cell 14, 523-529 (Pubitemid 38648805)
55. Peng, J. et al. (2006) tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation. Journal of Biological Chemistry 281, 35802-35811 (Pubitemid 46041312)
56. Szegezdi, E. et al. (2009) Bcl-2 family on guard at the ER. American Journal of Physiology - Cell Physiology 296, C941-C953
57. 2+: a control point for apoptosis. Science 300, 135-139
58. 2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death. Journal of Biological Chemistry 280, 23829-23836
59. Maiuri, M.C. et al. (2007) BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 3, 374-376 (Pubitemid 46986348)
60. Luo, X. et al. (2005) Transcriptional upregulation of PUMA modulates endoplasmic reticulum calcium pool depletion-induced apoptosis via Bax activation. Cell Death and Differentiation 12, 1310-1318 (Pubitemid 41486101)
61. Sandoval, H. et al. (2008) Essential role for Nix in autophagic maturation of erythroid cells. Nature 454, 232-235 (Pubitemid 351969889)
62. Lisbona, F. et al. (2009) BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha. Molecular Cell 33, 679-691
63. Rashmi, R. et al. (2008) BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells. Oncogene 27, 1366-1375 (Pubitemid 351317469)
64. Sinha, S. and Levine, B. (2008) The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene 1 (Suppl), 137-148
65. Chang, N.C. et al. (2010) Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulumrequires NAF-1. EMBOJournal 29, 606-618
66. Rong, Y.P. et al. (2009) Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. Biochimica et Biophysica Acta 1793, 971-978
67. Breckenridge, D.G. et al. (2003) Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. Journal of Cell Biology 160, 1115-1127 (Pubitemid 36443879)
68. Kuo, T.H. et al. (1998) Modulation of endoplasmic reticulum calcium pump by Bcl-2. Oncogene 17, 1903-1910 (Pubitemid 28488458)
69. Moenner, M. et al. (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Research 67, 10631-10634 (Pubitemid 350145884)
70. Carrasco, D.R. et al. (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11, 349-360 (Pubitemid 46518314)
71. Xu, C., Bailly-Maitre, B. and Reed, J.C. (2005) Endoplasmic reticulum stress: cell life and death decisions. Journal of Clinical Investigation 115, 2656-2664 (Pubitemid 41434389)
72. Kim, R. et al. (2006) Role of the unfolded protein response in cell death. Apoptosis 11, 5-13 (Pubitemid 43151639)
73. Ron, D. and Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology 8, 519-529 (Pubitemid 46985379)
74. Lin, J.H. et al. (2007) IRE1 signaling affects cell fate during the unfolded protein response. Science 318, 944-949 (Pubitemid 350098984)
75. Rosenfeldt, M.T. and Ryan, K.M. (2009) The role of autophagy in tumour development and cancer therapy. Expert Reviews in Molecular Medicine 11, e36
76. Axe, E.L. et al. (2008) Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. Journal of Cell Biology 182, 685-701
77. Kihara, A. et al. (2001) Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Reports 2, 330-335 (Pubitemid 32401529)
78. Liang, X.H. et al. (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672-676 (Pubitemid 129516338)
79. Pattingre, S. et al. (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122, 927-939 (Pubitemid 41345209)
80. Levine, B., Sinha, S. and Kroemer, G. (2008) Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4, 600-606
81. Bonapace, L. et al. (2010) Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation 120, 1310-1323
82. White, E. and DiPaola, R.S. (2009) The double-edged sword of autophagy modulation in cancer. Clinical Cancer Research 15, 5308-5316
83. Bellodi, C. et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. Journal of Clinical Investigation 119, 1109-1123
84. Whitecross, K.F. et al. (2009) Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113, 1982-1991
85. Hinds, M.G. et al. (2003) The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO Journal 22, 1497-1507 (Pubitemid 36417399)
86. O'Brien, S.M. et al. (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113, 299-305
87. Mason, K.D. et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128, 1173-1186 (Pubitemid 46427871)
88. Tse, C. et al. (2006) The Bcl-2 family protein inhibitor, ABT-263, promotes apoptosislike response in isolated platelets. Blood (ASH Annual Meeting Abstracts) 108, 1122
89. Elmore, S.W. et al. (2006) Bcl-2 family protein inhibitors induce a unique thrombocytopenia in vivo. Blood (ASH Annual Meeting Abstracts) 108, 4236
90. Shoemaker, A.R. et al. (2006) The Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice. Blood (ASH Annual Meeting Abstracts) 108, 1107
91. Wilson, W.H. et al. (2009) Phase 1/2a study of ABT-263 in relapsed or refractory lymphoid malignancies. Blood (ASH Annual Meeting Abstracts) 114, 1711
92. Roberts, A.W. et al. (2009) An ongoing phase 1/2a study of ABT-263; pharmacokinetics (PK), safety and antitumor activity in patients (pts) with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114, 883
93. Wilson, W.H. et al. (2008) Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies. Blood (ASH Annual Meeting Abstracts) 112, 2108
94. Khaw, S.K. et al. (2009) Biomarkers and in vivo responses to the BH3 mimetic, ABT-263, in patients (pts) with chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114, 2374
95. Schimmer, A.D. et al. (2008) A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clinical Cancer Research 14, 8295-8301
96. Knight, Z.A., Lin, H. and Shokat, K.M. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10, 130-137